Relmada’s depression drug fails to meet late-stage study goal
Relmada will continue to study REL-1017, its lead treatment, as an adjuntive or in combination with other depression drugs
Relmada Therapeutics said yesterday its therapy to treat major depressive disorder did not meet the main goal of a late-stage study.
The drug, REL-1017, did not show statistically significant improvement in symptoms of depression when compared to a placebo.
Relmada will continue to study REL-1017, its lead treatment, as an adjuntive or in combination with other depression drugs.
Major depressive disorder is a chronic condition that makes patients feel low, experience guilt and worthlessness. In extreme cases, it may lead to suicide.
Edits by EP News Bureau
- Advertisement -